Recipharm Laboratories

Recipharm Laboratories Inc., a contract pharmaceutical development company, develops inhalation and nasal products, including pressurized metered dose and dry powder inhalers; nebulizer solutions and suspensions; nasal sprays; novel delivery systems; oral dosage forms, including liquids, powders, and capsules; parenteral products; and topical and transdermal dosage forms, such as gels, creams, ointments, lotions, pastes, and sprays. The company’s services include analytical services; preformulation; formulation development; device evaluation; stability testing; development and validation of analytical chemical methods, stability studies, and regulatory support, and manufacturing support. It offers its services to pharmaceutical, biotechnology, veterinary, cosmetic, and consumer health industries worldwide. Recipharm Laboratories Inc. was formerly known as Cirrus Pharmaceuticals, Inc. and changed its name to Recipharm Laboratories Inc. in May 2016. The company was founded in 1997 and is based in Morrisville, North Carolina. As of May 23, 2016, Recipharm Laboratories Inc. operates as a subsidiary of Recipharm AB (publ).

Carl-Johan Spak

General Manager

13 past transactions

Kemwell Biopharma

Acquisition in 2016
Kemwell provides customized process/ product development and manufacturing solutions to pharmaceutical and biopharmaceutical organizations worldwide.
Corvette Group Pharmaceutical Services S.p.A. is the Parent Company of firms operating as suppliers of high value added services for the pharmaceutical industry. Corvette Group is controlled by LBO Italia Investimenti S.p.A. , an industrial, long-term private equity Holding firm with the objective of developing its subsidiaries in accordance with the highest level of ethical and professional standards. It supports the development plans of its subsidiaries in financial terms, by providing them capital, and in industrial and managerial terms, with its highly professional management structure. In addition to its managers, who own a significant share of the capital, LBO’s shareholders include important International investors like financial institutions, family offices and qualified entrepreneurs.

Sanofi - business

Acquisition in 2018
Sanofi - business is inhalation contract manufacturing business.

Cirrus Pharmaceuticals

Acquisition in 2016
Cirrus was founded in 1997 and is based in the Research Triangle Park, NC. We are registered with the U.S. Food & Drug Administration (FDA) as a cGMP Analytical Testing Facility. A combination of our scientific expertise and timely delivery of quality services have resulted in a high rate of customer satisfaction. We collaborate with companies across the globe, providing full product development as well as task-based services. Our scientists offer proven expertise in all dosage forms, including inhaled, nasal, oral, parenteral, and topical & transdermal. Cirrus understands our quality services are directly related to the project results you want to achieve. With this in mind, our processes are designed to ensure budgets and timelines are met and that we provide the overall value to exceed your expectations.

Consort Medical

Acquisition in 2019
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices in Europe, the United States, the United Kingdom, and internationally. It operates through two segments, Bespak and Aesica. The company provides various life improving treatments to patients worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products. It also develops, formulates, and manufactures active pharmaceutical ingredients, such as flurbiprofen, and finished dose drugs. Consort Medical plc was incorporated in 1946 and is based in Hemel Hempstead, the United Kingdom. As of April 2, 2020, Consort Medical plc operates as a subsidiary of Recipharm Holdings Limited.

MITIM S.r.l.

Acquisition in 2016
In 1981 the manufatoring process was moved into the the production plant which was owned by the Moroni family in the year 1969. in 1982, pursuing a far-sighted industrial policy, the Company decided to build a new and advanced production plant where the present head office in Brescia now resides. The production plant has been constantly improved over the years with the creation of new manufacturing, services and research areas in order to cope with the increased production requirements and higher standards of quality.

AstraZeneca Biotech Laboratory

Acquisition in 2008
AstraZeneca Biotech Laboratory engages in research of proteins produced by disease genes. The company is based in Södertälje, Sweden. As of January 1, 2009, AstraZeneca Biotech Laboratory operates as a subsidiary of Recipharm AB.

Cobra Biomanufacturing

Acquisition in 2009
Cobra Biomanufacturing operates as a contract manufacturer of biopharmaceuticals.

OnTarget Chemistry

Acquisition in 2015
OnTarget Chemistry is specialized in medicinal chemistry offering synthesis and analytical services.


Acquisition in 2014
It might be simplistically stated that Lusomedicamenta is specialised in the manufacture of pharmaceutical products: solids, liquids and semi-solids. It might the be added the the company is focused on new products carrying out the management of the entire process under a key-in-hand system from product creation the the registration dossier. It would also be no exaggeration to declare that, and without ever deviating on the highest of quality standard, Lusomedicamenta produces over 150 formulas and cover 700 formats, exporting its products to over 45 countries worldwide. Each and every on of these statements, remais correct but still fails to define us. We are defined by our staff. Competent, highly qualified people, motivaded by innovative and future oriented projects and more than able to manage scope for expansion through competitive cost, swift creative processes and a pragmatic, flexible, innovative and creative vision. These are, unquestionably, the core competences ans assets that ensure the sastisfaction and confidence of our clients wich have enabled Lusomedicamenta to establish its position as a leading benchmark for the pharmaceutical sector.

Flamel Technologies

Acquisition in 2014
Flamel Technologies SA is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently markets three previously Unapproved Marketed Drugs ("UMDs") in the United States, Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection), and Akovaz™ (ephedrine sulfate injection). The Company also develops products utilizing its proprietary drug delivery platforms, Micropump® (oral sustained release microparticles platform), along with its tangent technologies, LiquiTime® (a Micropump-derivative platform for liquid oral products) and Trigger Lock™ (a Micropump-derivative platform for abuse-resistant opioids). Additionally, the Company has developed a long acting injectable platform, Medusa™, a hydrogel depot technology, particularly suited to the development of subcutaneously administered formulations. Current applications of Flamel's drug delivery products include sodium oxybate (Micropump®), extended-release of liquid medicines such as ibuprofen and guaifenesin (LiquiTime®, through a license arrangement with Elan Pharma International Limited for the U.S. Over-the-Counter market) and a current study of the delivery of exenatide utilizing the Medusa™ technology.

Kemwell’s pharmaceutical businesses

Acquisition in 2017
Kemwell’s pharmaceutical businesses

Nitin Lifesciences Ltd

Acquisition in 2015
NITIN is a rapidly growing Indian pharmaceutical company with a strong presence in Injectable manufacturing. Nitin has three WHO-GMP Certified plants located at Karnal (Haryana) about 129 Kms. from our capital New Delhi and Paonta Sahib (Himachal Pradesh) in excise free zone.